{"id":948818,"date":"2026-04-02T16:23:03","date_gmt":"2026-04-02T20:23:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"modified":"2026-04-02T16:23:03","modified_gmt":"2026-04-02T20:23:03","slug":"praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","title":{"rendered":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, April  02, 2026  (GLOBE NEWSWIRE) &#8212; Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis\u2019 Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees\u2019 entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"left\">The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals\u2019 entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"left\">The restricted stock units will vest in four equal annual installments, subject to the employee\u2019s continued employment with Praxis on each vesting date.<\/p>\n<p align=\"left\">\n        <strong>About Praxis<\/strong><br \/>\n        <br \/>Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum\u2122, and antisense oligonucleotide (ASO) platform, Solidus\u2122, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cn--yuvCTd7KwMzS1xYrKeL6c0zUv8Ikb45WCKPDVjsZUez2pM652STgZKmueWOhxzS0EMr9eRIkW_dYKUiM4Wlk32hAQ6w7Fo8dQ4EVvhk=\" rel=\"nofollow\" target=\"_blank\">www.praxismedicines.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LCltw7juj9yID4J5wU251Jz835fUucoJ5VQ1bBARr1oNDDE6gVoGNak2pK4RFR7F_j_QBkbBJaLNNHe9VDR_w1LGm4uQ2llv9w03QcDudNe7CweoJzQKyO8YBmDldN1cjBKv2R4S58N4EvC_dhAQF7E-0zqNYmfLTahCct87O-zm-8TGwTd-81BuFRTRUiCNcJ_MTHZ3f06RJR-h0U49GoKtD_t_mXM62KmJTVauSCoIPQiOoh9Hl7gpoKVID2EmfUj1gqo83kM7M9Po_J_JkQ==\" rel=\"nofollow\" target=\"_blank\"><u>Facebook<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7M-Qfa-lQbsupcoafYp0tfzh7eBRMPOSbqvGty1EAIIFTliPJoVRqQCOjV_jBW3DNDe1ntFOiDk8D_0B2jarQ-juQ2HzDh-PvpvIvpApfDWEpMKV0CzlyuC_b4S00XiuWgt6ETH2ro9yX3u6horWDtj2PUSQAP8jqQE9kNBJkHSSbaP6os-kwDGvfQH9F1x32qxOYWzb-2c2-G6SqAP1bm8xjbv7fCABu9X9gtKs48xn6tGuPZa6TxKOQUwcG4mL6MLUx4lWUkThiU0Fhn5fjkUwdr5FPahOL2Mw6QE6t-BnphdsWPYO0xgjmOJ6uaNC\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BMd7LKmK9hhmMnJVfnuP84F0eJF7uGWSDVVjkFdortnsgktAmInJml72mVNCzl8MQPVY4oPey1jDRw3WH6Zr79Uq2q0x1nrvlNElm_P8Y5-E5EVlAgkpsbtg1NCUpMXJOwwwnQTOMrkIBRjTiq1dFq4ASsUfsAsG2bu2v_PsiMQjCq5NWLcRoVfSdXuCDJl6-m5oeHjTyr167idnPFh2lHbNvDhLn8uZjpuHge_xehzqptWJfFXGysd_oFNkBM3X\" rel=\"nofollow\" target=\"_blank\"><u>Twitter\/X<\/u><\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWJmNjZjZjMtZDA5ZS00OGZkLWI5ZTQtNzQzZTBiYjAzMmQwLTEyMTI0NDktMjAyNi0wNC0wMi1lbg==\/tiny\/Praxis-Precision-Medicines-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts:\r\nInvestor Contact:\r\nPraxis Precision Medicines\r\ninvestors@praxismedicines.com\r\n857-702-9452\r\n\r\nMedia Contact:\r\nDan Ferry\r\nLifeSci Advisors\r\nDaniel@lifesciadvisors.com\r\n617-430-7576<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis\u2019 Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees\u2019 entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-948818","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis\u2019 Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees\u2019 entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, &hellip; Continue reading &quot;Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T20:23:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-04-02T20:23:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\",\"name\":\"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\",\"datePublished\":\"2026-04-02T20:23:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","og_locale":"en_US","og_type":"article","og_title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis\u2019 Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees\u2019 entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, &hellip; Continue reading \"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-02T20:23:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-04-02T20:23:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","name":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=","datePublished":"2026-04-02T20:23:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzYzNSM3NTE3Njc5IzIyMDA4OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=948818"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948818\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=948818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=948818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=948818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}